- Raw materials
- Amino acids
- N-Acetylalanine
N-Acetylalanine API Manufacturers & Suppliers
0 verified results
All N-Acetylalanine data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
N-Acetylalanine | CAS No: 97-69-8 | GMP-certified suppliers
A medication that serves as an experimental amino acid derivative primarily used in research involving amino acid metabolism and transport in various therapeutic areas.
Therapeutic categories
Product Snapshot
- N-Acetylalanine is a small molecule compound typically utilized in oral formulations
- It is primarily investigated for potential applications in metabolic and neuromodulatory therapies
- The compound is currently in the experimental stage and has not yet received regulatory approval from major agencies such as the FDA or EMA
Clinical Overview
Pharmacodynamic properties and detailed mechanism of action have not been characterized or reported in the available literature. Consequently, no definitive information exists regarding its biological target interactions or physiological effects. As a modified amino acid derivative, it may potentially participate in biochemical pathways involving amino acid transport or metabolism, but these activities require further elucidation through preclinical and clinical studies.
Absorption, distribution, metabolism, and excretion (ADME) parameters for N-Acetylalanine have not been systematically described. Generally, N-acetylated amino acid derivatives may exhibit altered solubility and transport profiles compared to their parent amino acids. However, specific pharmacokinetic data including bioavailability, half-life, metabolic pathways, and routes of elimination remain unavailable.
Safety and toxicity profiles have not been established. Without rigorous toxicological assessment, the potential for adverse effects or toxicities cannot be determined. At present, its use is restricted to experimental research contexts, and no marketed pharmaceutical formulations contain this compound as an active ingredient.
In terms of sourcing and quality control, procurement of N-Acetylalanine for pharmaceutical research requires careful consideration of purity, stereochemical configuration, and compliance with relevant pharmacopeial or analytical standards. Reliable suppliers should provide certificates of analysis confirming the absence of contaminants and verification of the L-configuration, given the compound's chiral nature, to ensure consistency and reproducibility in experimental applications.
Identification & chemistry
| Generic name | N-Acetylalanine |
|---|---|
| Molecule type | Small molecule |
| CAS | 97-69-8 |
| UNII | 26C4VY6Z0M |
| DrugBank ID | DB02518 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Aldose reductase | Humans |
Formulation & handling
- N-Acetylalanine is a small molecule amino acid derivative suitable for oral formulations due to its solid state and high water solubility.
- The compound's low logP value (-0.76) indicates hydrophilicity, which may affect membrane permeability and formulation strategies.
- No specific stability or food interaction data are noted, suggesting standard handling and storage conditions are appropriate.
Regulatory status
N-Acetylalanine is a type of Amino acids
Amino acids are an essential category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the pharmaceutical industry. These organic compounds are the building blocks of proteins and play a crucial role in various biological processes. With their increasing popularity and therapeutic potential, amino acids have become a focus of research and development in drug discovery.
Amino acids can be classified into two main categories: essential and non-essential. Essential amino acids cannot be synthesized by the body and must be obtained from dietary sources or through pharmaceutical supplementation. Non-essential amino acids, on the other hand, can be synthesized by the body itself.
Pharmaceutical-grade amino acids are produced through a variety of methods, including extraction from natural sources, fermentation, and chemical synthesis. They undergo rigorous quality control procedures to ensure purity, efficacy, and safety. The most common amino acids used as APIs include lysine, valine, leucine, isoleucine, phenylalanine, and methionine, among others.
Amino acids have diverse applications in the pharmaceutical industry. They are widely used as ingredients in parenteral nutrition formulations, where they provide essential nutrients to patients who cannot consume food orally. Additionally, amino acids are utilized in the development of protein-based drugs, such as monoclonal antibodies and recombinant proteins. These pharmaceutical proteins often require specific amino acid sequences to achieve desired therapeutic effects.
In conclusion, amino acids are a vital category of pharmaceutical APIs, playing a significant role in protein synthesis, nutrition, and the development of protein-based drugs. With their extensive applications and growing demand, amino acids continue to contribute to advancements in the pharmaceutical industry.
